Assertio Holdings (Assertio Holdings) Gross Margin % : 70.53% (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Assertio Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Assertio Holdings's Gross Profit for the three months ended in Dec. 2023 was $23.3 Mil. Assertio Holdings's Revenue for the three months ended in Dec. 2023 was $33.0 Mil. Therefore, Assertio Holdings's Gross Margin % for the quarter that ended in Dec. 2023 was 70.53%.

Warning Sign:

Assertio Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -2.5%.

The historical rank and industry rank for Assertio Holdings's Gross Margin % or its related term are showing as below:

ASRT' s Gross Margin % Range Over the Past 10 Years
Min: 80.19 Med: 83.99 Max: 96.12
Current: 82.23

During the past 13 years, the highest Gross Margin % of Assertio Holdings was 96.12%. The lowest was 80.19%. And the median was 83.99%.

ASRT's Gross Margin % is ranked better than
93.64% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.74 vs ASRT: 82.23

Assertio Holdings had a gross margin of 70.53% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Assertio Holdings was -2.50% per year.

Assertio Holdings Gross Margin % Historical Data

The historical data trend for Assertio Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assertio Holdings Gross Margin % Chart

Assertio Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

95.86

81.30

85.74

88.00

82.23

Assertio Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															88.06	87.13	88.36	80.18	70.53

Competitive Comparison of Assertio Holdings's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assertio Holdings's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Assertio Holdings's Gross Margin % falls into.

Assertio Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Assertio Holdings's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	125	/	152.069
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(152.069 - 27.02)	/	152.069
	=	82.23 %

Assertio Holdings's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	23.3	/	32.985
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(32.985 - 9.721)	/	32.985
	=	70.53 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Assertio Holdings (NAS:ASRT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Assertio Holdings had a gross margin of 70.53% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Assertio Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Assertio Holdings (Assertio Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (NAS:ASRT) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045

Website

https://www.assertiotx.com

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Executives

Daniel A. Peisert	director, officer: President & CEO	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Paul Schwichtenberg	officer: SVP and CFO	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Ajay Patel	officer: SVP and CAO	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Sam Schlessinger	officer: SVP, General Counsel	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FORREST IL 60045
William Mckee	director
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Heather L Mason	director	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Mark Strobeck	officer: EVP & Chief Operating Officer	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Andrea Heslin Smiley	director	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Megan C. Timmins	officer: SVP, Gen Csl & Sec	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002